Please assess the completion status of the following clinical trial:

Trial Title: Continuation of Nintedanib After Single Lung Transplantation in IPF Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults between the ages of 35-70.~* Lung transplantation listing diagnosis of pulmonary fibrosis~* Recipient of single lung transplantation within the past 60 days~Exclusion Criteria:~* History of intolerability to nintedanib (i.e. discontinued nintedanib in the pre-transplant period due to adverse drug effects)~* Liver transaminase elevation (AST or ALT \> 1.5X the upper limit of normal)~* Total bilirubin \> 1.5X the upper limit of normal~* Drugs that interfere with the metabolism or elimination of nintedanib or its metabolites - St. John's wort, carbamazepine, phenytoin, rifampin, dexamethasone, and others.~* Any history of bronchial anastomosis dehiscence or stenosis~* Bleeding risk, defined as any of the following:~  * Full-dose therapeutic anticoagulation (i.e. vitamin K antagonist, direct thrombin inhibitors, etc.)~ * History of hemorrhagic central nervous system (CNS) event within 12 months of enrollment~ * Coagulation parameters: international normalized ratio (INR) \> 2, prolongation of prothrombin time (PT) and partial thromboplastin time (PTT) by \> 1.5X the upper limit of normal at enrollment

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Nintedanib (Type: EXPERIMENTAL): Nintedanib 150 mg tablet by mouth twice daily for 24 months.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo tablet by mouth twice daily for 24 months

Based on this trial design, predict the completion outcome and termination type (if applicable).